XERS Xeris Pharmaceuticals Inc

Price (delayed)

$8.66

Market cap

$1.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.1

Enterprise value

$1.75B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 53

Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: ...

Highlights
XERS's EPS has soared by 52% year-on-year
The net income has grown by 46% YoY
XERS's equity has dropped by 175% since the previous quarter but it is up by 50% year-on-year
XERS's quick ratio is down by 33% since the previous quarter and by 19% year-on-year
The debt has grown by 13% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of XERS

XERS stock price

How has the Xeris Pharmaceuticals stock price performed over time
Intraday
-0.8%
1 week
11.31%
1 month
-0.46%
1 year
9.48%
YTD
10.32%
QTD
9.34%

Financial performance

How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$335.41M
Gross profit
$290.39M
Operating income
$36.59M
Net income
-$17.17M
Gross margin
86.6%
Net margin
-5.1%
The net margin has soared by 61% YoY
The net income has grown by 46% YoY
The gross profit has grown by 44% YoY and by 7% from the previous quarter
The company's revenue rose by 36% YoY and by 7% QoQ

Price vs fundamentals

How does XERS's price correlate with its fundamentals

Growth

What is Xeris Pharmaceuticals's growth rate over time

Valuation

What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
4.46
EV/EBIT
157.53
EV/EBITDA
73.1
EV/Sales
5.21
XERS's EPS has soared by 52% year-on-year
XERS's equity has dropped by 175% since the previous quarter but it is up by 50% year-on-year
XERS's price to sales (P/S) is 45% more than its 5-year quarterly average of 3.1 and 10% more than its last 4 quarters average of 4.1
The company's revenue rose by 36% YoY and by 7% QoQ

Efficiency

How efficient is Xeris Pharmaceuticals business performance
XERS's return on equity has dropped by 158% since the previous quarter
XERS's ROS has dropped by 74% since the previous quarter
The return on invested capital has dropped by 72% since the previous quarter
The return on assets has surged by 56% year-on-year

Dividends

What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XERS.

Financial health

How did Xeris Pharmaceuticals financials performed over time
The total assets is 2.3% less than the total liabilities
XERS's quick ratio is down by 33% since the previous quarter and by 19% year-on-year
XERS's current ratio is down by 32% since the previous quarter and by 26% year-on-year
XERS's equity has dropped by 175% since the previous quarter but it is up by 50% year-on-year
The debt to equity has plunged by 123% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.